AM-1638 - Moligand™, 10mM in DMSO , CAS No.1142214-62-7
En stock
SKU
A655181
AM-1638 is a potent and orally bioavailable GPR40/FFA1 full agonist with an EC 50 of 0.16 μM.
In Vivo
AM-1638 exhibits moderate cross-species plasma clearance and volume of distribution, resulting in plasma half-lives suitable for evaluation of its antidiabetic properties in mouse, rat, and cynomologus monkey. Moreover, oral administration of full agonist AM-1638 demonstrates excellent oral bioavailability (mouse, >100%; rat, 72%; and cyno, 71%). AM-1638\nexhibits antidiabetic activity in BDF/DIO mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
IC50& Target:IC50: 0.16 μM (GPR40/FFA1)
Plus d’information
| CAS | 1142214-62-7 |
|---|---|
| Concentration | 10mM in DMSO |
| Spécifications et pureté | Moligand™, 10mM in DMSO |
| Conditions de stockage de stockage | Protected from light,Store at -80°C |
| Expédié en | Dry ice packs + Cold packs |
| Product Description | AM-1638 is a potent and orally bioavailable GPR40/FFA1 full agonist with an EC 50 of 0.16 μM. In Vivo AM-1638 exhibits moderate cross-species plasma clearance and volume of distribution, resulting in plasma half-lives suitable for evaluation of its antidiabetic properties in mouse, rat, and cynomologus monkey. Moreover, oral administration of full agonist AM-1638 demonstrates excellent oral bioavailability (mouse, >100%; rat, 72%; and cyno, 71%). AM-1638\nexhibits antidiabetic activity in BDF/DIO mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:IC50: 0.16 μM (GPR40/FFA1) |
| Cible | FFAR1 |
Avis
Avis des clients
Remind me later